Almirall's aclidinium adventure continues with EU approval
This article was originally published in Scrip
The European Commission has granted Almirall's aclidinium bromide product approval in all EU member states, plus Iceland and Norway. The approval was expected after the CHMP gave the drug a positive opinion in May covering use as a maintenance bronchodilator treatment to relieve symptoms in patients with COPD (scripintelligence.com, 25 May 2012). US approval too is expected in July.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.